Literature DB >> 32334375

The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis.

Shengjie Xu1, Yingchao Gong1, Ying Yin2, Hongyuan Xing3, Ning Zhang4.   

Abstract

Osteosarcoma is a bone tumor prevalent in children and young adults. LncRNAs are a family of non-protein-coding transcripts longer than 200 nucleotides. The tumor-related pathological functions of lncRNAs include proliferation, migration, and chemotherapy resistance, all of which have been widely acknowledged in research on osteosarcoma. In addition, compelling evidence suggests that lncRNAs could serve as diagnostic indicators, prognostic biomarkers, and targets for disease treatment. In this review, we systematically summarize how lncRNAs regulate tumorigenesis, invasion and therapeutic resistance. By deepening our knowledge of the relationship between lncRNAs and osteosarcoma, we hope to translate research findings into clinical applications as soon as possible.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Long noncoding RNA; Osteosarcoma; Prognosis; Resistance; Signaling pathways

Year:  2020        PMID: 32334375     DOI: 10.1016/j.biopha.2020.110141

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

Review 1.  Role of autophagy in drug resistance and regulation of osteosarcoma (Review).

Authors:  Yanchuan Pu; Jin Wang; Shizhong Wang
Journal:  Mol Clin Oncol       Date:  2022-02-01

2.  N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.

Authors:  Kun Yang; Fengyan Wang; Ke Li; Guoxuan Peng; Hua Yang; Hong Xu; Yang Xiang; Hong Sun
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  GAS5‑mediated regulation of cell signaling (Review).

Authors:  Yang Zhou; Binghai Chen
Journal:  Mol Med Rep       Date:  2020-08-19       Impact factor: 2.952

4.  Long Noncoding RNA CCDC144NL-AS1 Promotes the Oncogenicity of Osteosarcoma by Acting as a Molecular Sponge for microRNA-490-3p and Thereby Increasing HMGA2 Expression.

Authors:  Juliang He; Jian Guan; Shian Liao; Zhenjie Wu; Bin Liu; Hao Mo; Zhenchao Yuan
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

5.  lncRNA TUSC7 inhibits osteosarcoma progression through the miR‑181a/RASSF6 axis.

Authors:  Aiqing Zhao; Wanlin Liu; Xiaolong Cui; Na Wang; Yuxin Wang; Liang Sun; Huiqin Xue; Lishuan Wu; Shuxia Cui; Yun Yang; Rui Bai
Journal:  Int J Mol Med       Date:  2020-12-18       Impact factor: 4.101

6.  lncRNA HCG11 suppresses human osteosarcoma growth through upregulating p27 Kip1.

Authors:  Jie Gu; Bo Dai; Xuchao Shi; Zhennian He; Yuanlin Xu; Xiangqian Meng; Junlan Zhu
Journal:  Aging (Albany NY)       Date:  2021-09-13       Impact factor: 5.682

7.  Transcriptome profiling of lncRNA and co-expression network in the vaginal epithelial tissue of women with lubrication disorders.

Authors:  Jingjing Zhang; Jing Zhang; Shengnan Cong; Jingyi Feng; Lianjun Pan; Yuan Zhu; Aixia Zhang; Jiehua Ma
Journal:  PeerJ       Date:  2021-11-10       Impact factor: 2.984

8.  Knockdown of lncRNA LINC00662 suppresses malignant behaviour of osteosarcoma cells via competition with miR-30b-3p to regulate ELK1 expression.

Authors:  Bin Wang; Zhengfeng Xu; Xiuhui Wang; Shengli Xia; Pan Cai; Minghui Wang; Zhenchao Gao
Journal:  J Orthop Surg Res       Date:  2022-02-05       Impact factor: 2.359

9.  Long Noncoding RNA DICER1-AS1 Functions in Methylation Regulation on the Multi-Drugresistance of Osteosarcoma Cells via miR-34a-5p and GADD45A.

Authors:  Feng Wang; Lingsuo Kong; Youguang Pu; Fengmei Chao; Chunbao Zang; Wei Qin; Fangfang Zhao; Shanbao Cai
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

10.  Effects of lncRNA TUSC7 on the malignant biological behavior of osteosarcoma cells via regulation of miR-375.

Authors:  Lulu Wang; Jiankui Jiang; Guisen Sun; Panpan Zhang; Ya Li
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.